Antiviral drugs and acute kidney injury

doi:10.3877/cma.j.issn.2095-3216.2023.05.009

Abstract

Abstract:

Antiviral drugs are commonly used in clinical practice, and may lead to acute kidney injury through a variety of mechanisms, including renal hypoperfusion, direct renal tubular toxicity, crystal nephropathy, and thrombotic microangiopathy, etc. The pandemic of COVID-19 has brought antiviral drug-associated kidney injury to extensive clinical focus. This article reviewed the performances of antiviral drugs in COVID-19 treatment and their effect on the kidney, and summarized the clinical manifestations and pathological mechanisms of antiviral drug-associated acute kidney injury.

Key words: Antiviral drugs, Acute kidney injury, COVID-19

Jinpu Li, Xiangrong Rao. Antiviral drugs and acute kidney injury[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 287-290.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2023.05.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2023/V12/I05/287

Figures/Tables 2

References 37

[1]	谢院生. 药源性肾损害的诊治与预防[J/CD]. 中华肾病研究电子杂志，2021, 10(2): 120.
[2]	Nunes LLA, Lima TM. Use of medicines for covid-19 treatment in patients with loss of kidney function: a narrative review [J]. J Bras Nefrol, 2021, 43(2): 254-262.
[3]	Ng JH, Bijol V, Sparks MA, et al. Pathophysiology and pathology of acute kidney injury in patients with COVID-19 [J]. Adv Chronic Kidney Dis, 2020, 27(5): 365-376.
[4]	Palevsky PM. COVID-19 and AKI: where do we stand? [J]. J Am Soc Nephrol, 2021, 32(5): 1029-1032.
[5]	Jonny J, Violetta L, Kartasasmita AS, et al. Pharmacological treatment options for coronavirus disease-19 in renal patients [J]. Int J Nephrol, 2021, 2021: 4078713.
[6]	Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report [J]. N Engl J Med, 2020, 383(19): 1813-1826.
[7]	Mahase E. Covid-19: Pfizer′s paxlovid is 89% effective in patients at risk of serious illness, company reports [J]. BMJ, 2021, 375: n2713.
[8]	Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients [J]. N Engl J Med, 2022, 386(6): 509-520.
[9]	Pettit NN, Pisano J, Nguyen CT, et al. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? [J]. Clin Infect Dis, 2021, 73(11): e3990-e3995.
[10]	Chouchana L, Preta LH, Tisseyre M, et al. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study [J]. Kidney Int, 2021, 99(5): 1235-1236.
[11]	Gerard AO, Laurain A, Fresse A, et al. Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database [J]. Clin Pharmacol Ther, 2021, 109(4): 1021-1024.
[12]	Silva NAO, Zara A, Figueras A, et al. Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database [J]. Cad Saude Publica, 2021, 37(10): e00077721.
[13]	Abdelbary AA, Alharafsheh AE, Ahmed A, et al. Favipiravir-induced nephrotoxicity in a patient with COVID-19: a case report [J]. Clin Case Rep, 2021, 9(8): e04539.
[14]	Binois Y, Hachad H, Salem JE, et al. Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with COVID-19 [J]. Kidney Int Rep, 2020, 5(10): 1787-1790.
[15]	Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 [J]. N Engl J Med, 2020, 382(19): 1787-1799.
[16]	Arrestier R, Stehle T, Letavernier E, et al. Lopinavir-ritonavir associated acute kidney injury is not related to crystalluria in critically ill COVID-19 patients [J]. Kidney Int Rep, 2020, 5(11): 2119.
[17]	Schneider J, Jaenigen B, Wagner D, et al. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients [J]. PLoS One, 2021, 16(5): e0249760.
[18]	Prikis M, Cameron A. Paxlovid (nirmatelvir/ritonavir) and tacrolimus dug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report [J]. Transplant Proc, 2022, 54(6): 1557-1560.
[19]	Yücel HE. A case of acute renal failure with COVID-19 under molnupiravir treatment [J]. Med Sci Discov, 2022, 9(6): 371-374.
[20]	Nasa P, Shrivastava P, Kulkarni A, et al. Favipiravir induced nephrotoxicity in two patients of COVID-19 [J]. J Assoc Physicians India, 2021, 69(1): 90.
[21]	Launay M, Demartin AL, Ragey SP, et al. Severe inflammation, acute kidney injury, and drug-drug interaction: triple penalty for prolonged elimination of apixaban in patients with coronavirus disease 2019: a grand round [J]. Ther Drug Monit, 2021, 43(4): 455-458.
[22]	Dhampalwar S, Saigal S, Soin AS. Treatment armamentarium of COVID-19: evolving strategies and evidence so far [J]. J Clin Exp Hepatol, 2020, 10(6): 599-609.
[23]	Hashemian SMR, Pourhanifeh MH, Hamblin MR, et al. RdRp inhibitors and COVID-19: is molnupiravir a good option? [J]. Biomed Pharmacother, 2022, 146: 112517.
[24]	Leowattana W. Antiviral drugs and acute kidney injury (AKI) [J]. Infect Disord Drug Targets, 2019, 19(4): 375-382.
[25]	Soto K, Campos P, Manso R, et al. Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy [J]. Kidney Int Rep, 2019, 4(3): 494-499.
[26]	Novick TK, Choi MJ, Rosenberg AZ, et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report [J]. Medicine (Baltimore), 2017, 96(36): e8046.
[27]	Deiva A, Jayaprakash V, Jose N, et al. Acute kidney injury in a patient treated with tenofovir alafenamide fumarate for hepatitis B virus infection [J]. Saudi J Kidney Dis Transpl, 2021, 32(2): 592-594.
[28]	Ueaphongsukkit T, Gatechompol S, Avihingsanon A, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review [J]. AIDS Res Ther, 2021, 18(1): 53.
[29]	Bernhoff E, Gutteberg TJ, Sandvik K, et al. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression [J]. Am J Transplant, 2008, 8(7): 1413-1422.
[30]	Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure [J]. Clin Infect Dis, 1999, 29(4): 948-949.
[31]	Zhou Y, Wei M, Zhang M, et al. Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis [J]. Toxicol Lett, 2022, 359: 10-21.
[32]	Chavez-Iniguez JS, Medina-Gonzalez R, Aguilar-Parra L, et al. Oral acyclovir induced hypokalemia and acute tubular necrosis a case report [J]. BMC Nephrol, 2018, 19(1): 324.
[33]	Giustina A, Romanelli G, Cimino A, et al. Low-dose acyclovir and acute renal failure [J]. Ann Intern Med, 1988, 108(2): 312.
[34]	Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection [J]. Drugs, 1999, 58(6): 1165-1203.
[35]	Lodi L, Mastrolia MV, Bello F, et al. Type I interferon-related kidney disorders [J]. Kidney Int, 2022, 101(6): 1142-1159.
[36]	Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney [J]. Clin J Am Soc Nephrol, 2018, 13(2): 300-317.
[37]	Allinovi M, Cirami CL, Caroti L, et al. Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab [J]. Clin Kidney J, 2017, 10(5): 625-631.

抗病毒机制	药物	研究者	研究类型	引发AKI的可能机制
RdRp抑制剂	瑞德西韦	Pettit等^[9]、Chouchana等^[10]、Gerard等^[11]、Silva等^[12]	数据挖掘	SBECD肾毒性，瑞德西韦前药GS-441524累积，或线粒体和/或直接近端小管损伤
RdRp抑制剂	法匹拉韦	Abdelbary等^[13]、Nasa等^[20]	病例报道	GFR 30~50 ml/(min·1.73 m²)的患者中，血清浓度可增加2~3倍
HIV蛋白酶抑制剂	洛匹那韦/利托那韦	Binois等^[14]	病例系列	近端肾小管损伤
		Cao等^[15], Arrestier等^[16]	随机对照研究

抗病毒机制	药物	研究者	研究类型	引发AKI的可能机制
RdRp抑制剂	瑞德西韦	Pettit等^[9]、Chouchana等^[10]、Gerard等^[11]、Silva等^[12]	数据挖掘	SBECD肾毒性，瑞德西韦前药GS-441524累积，或线粒体和/或直接近端小管损伤
RdRp抑制剂	法匹拉韦	Abdelbary等^[13]、Nasa等^[20]	病例报道	GFR 30~50 ml/(min·1.73 m²)的患者中，血清浓度可增加2~3倍
HIV蛋白酶抑制剂	洛匹那韦/利托那韦	Binois等^[14]	病例系列	近端肾小管损伤
		Cao等^[15], Arrestier等^[16]	随机对照研究

药物组合	研究者	研究类型	引发AKI的可能机制
洛匹那韦/利托那韦联合羟氯喹	Schneider等^[17]	病例系列	洛匹那韦和羟氯喹均经CYP3A4酶代谢，存在相互作用
帕斯洛韦+他克莫司	Prikis等^[18]	病例报道	CYP3A4酶抑制剂利托那韦提高他克莫司血药浓度，导致急性他克莫司肾毒性
莫努匹韦+降压药物	YüCel ^[19]	病例报道	莫努匹韦通过减少肾组织血流灌注，引起缺血性肾损伤
洛匹那韦/利托那韦+阿哌沙班	Launay等^[21]	病例报道	CYP3A4酶抑制剂和P-gp抑制剂利托那韦减少阿哌沙班经肝肾、胃肠代谢，导致阿哌沙班血药浓度增加

药物组合	研究者	研究类型	引发AKI的可能机制
洛匹那韦/利托那韦联合羟氯喹	Schneider等^[17]	病例系列	洛匹那韦和羟氯喹均经CYP3A4酶代谢，存在相互作用
帕斯洛韦+他克莫司	Prikis等^[18]	病例报道	CYP3A4酶抑制剂利托那韦提高他克莫司血药浓度，导致急性他克莫司肾毒性
莫努匹韦+降压药物	YüCel ^[19]	病例报道	莫努匹韦通过减少肾组织血流灌注，引起缺血性肾损伤
洛匹那韦/利托那韦+阿哌沙班	Launay等^[21]	病例报道	CYP3A4酶抑制剂和P-gp抑制剂利托那韦减少阿哌沙班经肝肾、胃肠代谢，导致阿哌沙班血药浓度增加

Please choose a citation manager

Content to export